鴉片類藥物使用障礙（OUD）治療市場：現況分析與預測（2024-2032）

鴉片類藥物使用障礙（OUD）治療市場，由於公司擴張，預計將以 8.1%左右的速度穩定成長。例如，2022年11月，Indivior PLC和Opiant Pharmaceuticals, Inc.宣布，Indivior將以每股20美元現金的預付款（總計約1.45億美元）收購Opiant，收購期限為批准和推出後七年。公司已簽訂最終協議，以每股最高8 美元的或有價值收購該公司，在實現某些淨收入里程碑時支付。本次交易已獲得各公司董事會的一致批准。此次收購加強並擴大了 Indivior 作為成癮治療領域領導者的地位。此外，健康和保健趨勢的上升、治療中心數量的增加、與康復機構的合併以及政府對鴉片類藥物使用障礙的認識和治療的努力和資金的增加推動鴉片類藥物使用障礙（OUD）治療市場的成長。

依藥物類別，市場分為buprenorphine、methadone和naltrexone。buprenorphine在2023年擁有最高的市場佔有率，因為與其他治療藥物相比，它具有更高的療效和更少的副作用。buprenorphine屬於部分鴉片類促效劑家族，因其濫用和過量的可能性較低且有助於控制菸癮和戒斷症候群而受到高度重視。由於處方者和患者的接受度以及允許其分佈的監管因素，buprenorphine的使用日益增加。此外，緩釋製劑和聯合製劑等先進功能改善Welch的治療方案並促進市場成長。將buprenorphine納入治療方案並提高其對抗鴉片類藥物使用障礙的有效性的持續努力進一步推動了這一領域的成長。

依給藥途徑，市場分為經口藥物和非口藥藥物。由於經口製劑方便、有效且價格實惠，預計在預測期內將佔據重要的市場佔有率。buprenorphine和naltrexone都是經口藥物，且是非侵入性的，因此患者不必經常去醫生辦公室接受藥物。新分子和改進的藥物遞送系統，例如緩釋製劑和組合製劑，提供更大的功效和安全優勢。其他因素也起到了一定作用，例如治療方案中經口藥物的普遍接受度以及臨床醫生和患者意識的提高。這種成長反映了這樣一個事實：經口藥物對於製定 OUD 管理實用且有效的治療策略非常重要。因此，預計在預測期內，經口藥物部分將在給藥途徑中佔據重要的市場佔有率。

根據通路，市場分為醫院藥房、零售藥房/商店和網路藥房。市場區隔 由於消費者的存取選項、舒適度和匿名性不斷增加，線上藥局市場穩步成長。科技的進步使得透過數位健康平台、遠距醫療和線上藥局更容易獲得 OUD 處方和藥物，使患者能夠在舒適的家中私下管理自己的症狀。該細分市場進一步受益於改進的資料保護、更快的處方方法以及對以前未提供服務的區域的可及性。線上藥局增加遠距醫療服務和電子處方也透過擴大其在提供維持護理和持續藥物管理方面的作用，促進了該行業的成長。因此，預計線上藥局產業在預測期內的通路將顯著成長。

為了更了解鴉片類藥物使用疾患（OUD）治療藥物的市場導入，市場根據北美 (美國、加拿大、北美其他地區) 、歐洲 (德國、法國、英國、西班牙、義大利、歐洲其他地區) 、亞太地區 (中國、日本、印度、亞太其他地區) 和世界其他國家的全球布局進行分析。由於鴉片類藥物流行的持續增加以及對治療方案的了解不斷加深，北美將在2023年佔據大部分市場佔有率。該市場受到藥物輔助治療（MAT）需求不斷成長的推動，其中包括行為療法以及buprenorphine和methadone。此外，市場上新配方和治療方法的出現也被認為推動該領域的市場成長。進一步推動市場擴張的其他因素包括政府活動、增加藥物濫用治療服務的資金以及全球向多模式醫療保健的轉變。例如，2023年5月，美國食品藥物管理局核准Brixadi（buprenorphine）緩釋注射液用於皮下用途，用於治療中重度鴉片類藥物使用障礙（OUD）。 Brixadi 是一種每週一次的注射劑，可用於開始接受單劑量經黏膜buprenorphine治療或已經接受buprenorphine治療的患者，對於已經接受buprenorphine治療的患者，有兩種劑型。可以每月注射一次。這樣一來，2023年北美將在所有地區中佔據較大的市場佔有率。

目錄

第1章 市場介紹

• 市場定義
• 主要目的
• 利害關係人
• 限制

第2章 研究方法或前提

• 調查過程
• 調查方法
• 受訪者簡介

第3章 執行摘要

• 行業概況
• 依細分市場進行預測
  • 市場成長強度
• 區域展望

第4章 市場動態

• 促進因素
• 機會
• 抑制因素
• 趨勢
• PESTEL 分析
• 需求方分析
• 供給面分析
  • 併購
  • 投資場景
  • 產業洞察：主要新創公司及其獨特策略

第5章 價格分析

• 依地區價格分析
• 影響價格的因素

第6章 全球鴉片類藥物使用障礙（OUD）治療市場收入，2022-2032年

第7章 市場洞察：依藥物類別

• buprenorphine
• methadone
• naltrexone

第8章 市場洞察：依給藥途徑

• 經口
• 非經口

第9章 市場洞察：依通路

• 醫院藥房
• 零售藥局/商店
• 網路藥局

第10章 市場洞察：依地區

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 其他亞太地區
• 世界其他地區

第11章 鴉片類藥物使用疾患（OUD）治療狀態

第12章 價值鏈分析

• 邊際分析
• 進入市場的公司名單

第13章 競爭態勢

• 競爭儀表板
• 競爭市場定位分析
• 波特五力分析

第14章 公司簡介

• MediciNova, Inc.
• Aphios Corporation
• Braeburn Inc.
• Alkermes
• Indivior PLC
• Zynerba Pharmaceuticals, Inc.
• Mylan N.V.
• Janssen Global Services, LLC
• Sandoz AG
• Cumberland Pharmaceuticals Inc.

第15章 縮寫與先決條件

第16章 附錄

Opioid Use Disorder (OUD) requires medication, behavioral therapies, and supportive services for those struggling with addiction since it is a complex disease affecting the brain. Medications like methadone, buprenorphine, and naltrexone alleviate the withdrawal process and provide relief from cravings and opioid effects. Other behavioral therapies such as cognitive behavioral therapy and contingency management seek to change undesirable behaviors as well as incentivize recovery. Counseling, case management, and support groups help individuals continue to abstain from substance use and reintegrate into society. Holistic non-pharmacological approaches that exist include medication-assisted treatment (MAT) programs and OUD treatment strategies that are aimed at providing a rounded and comprehensive solution to treat the disorder.

The Opioid Use Disorder (OUD) Treatment Market is expected to grow at a steady rate of around 8.1% owing to the rising company expansions. For instance, in November 2022, Indivior PLC and Opiant Pharmaceuticals, Inc. entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of USD 20.00 per share, in cash (approximately USD 145 million in aggregate), plus up to USD 8.00 per share in contingent value rights that may become payable if certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the board of directors of each company. The acquisition strengthened and extended the Indivior's position as a leader in addiction treatment. Moreover, the rising health & wellness trends, a growing number of treatment centers, mergers with recovery institutions, and increasing initiatives & funding by the government for the awareness and treatment of opioid use disorder are leading to the growth of the opioid use disorder (OUD) treatment market.

Based on the drug class, the market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment held a significant market share in the market in the year 2023 owing to its effectiveness and side effects as compared to other treatment solutions. Buprenorphine belongs to the partial opioid agonist, and it is appreciable because it helps in managing craving and withdrawal syndrome with a low likelihood of abuse and overdose. The increased use of buprenorphine is due to the acceptance of prescribers and patients as well as regulatory factors that allow its distribution. Moreover, advanced features like extended-release formulations and combination products are improving the therapeutic profile of Welch and fueling the market's growth. The growth of this segment is further supported by the continuation of the efforts to incorporate buprenorphine into the treatment plans and enhance the efficacy in combating opioid use disorders.

Based on the route of administration, the market is bifurcated into oral and parenteral. The oral segment is expected to hold a significant market share in the forecast period as it is convenient, effective, and affordable. Both buprenorphine and naltrexone are orally administered drugs and are not invasive so patients do not have to constantly visit the clinic to receive this medication. New molecules have improved drug delivery systems including extended-release products and combination products have given them a further edge in terms of efficacy and safety. Other factors such as the general acceptance of oral medications in treatment protocols along with the growing realization on the part of clinicians and patients have also contributed. This growth reflects the fact that the oral segment has been highly important for the development of practical and effective treatment strategies for OUD management. Thus, the oral segment is expected to hold a significant market share in the forecast period among the route of administration methods.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & stores, and online pharmacies. The online pharmacies segment of the opioid use disorder (OUD) treatment market has witnessed robust growth owing to enhanced access options, comfort, and anonymity for consumers. Due to the advancement in technology, prescriptions and medications for OUD have been made more easily available through digital health platforms, telemedicine, and online pharmacies making it easy for the patients to deal with their conditions away from the public eye and in the comfort of their homes. This segment has been further benefiting from improved data protection, faster prescription methods, and accessibility to areas not previously served. Also, the inclusion of online pharmacies with telehealth services and electronic prescriptions has broadened their role in the provision of maintenance care and continuous medication management, which also has aided in the growth of this sector. Thus, the online pharmacies segment is expected to grow at a significant rate in the forecast period among the distribution channels.

For a better understanding of the market adoption of opioid use disorder (OUD) treatments, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the majority share of the market in the year 2023 because of the continuous increase in the opioid epidemic and a greater understanding of treatment programs. This market is boosted by increased demand for medication-assisted treatments (MAT), including buprenorphine and methadone as well as behavioral therapies. The arrival of new drug formulations and therapies in the market is also credited to have fueled market growth in this segment. Some of the other factors that are further driving market expansion include government campaigns, increasing funding for substance abuse treatment services, and global transitions towards combined care practices. For instance, in May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine. Thus, amongst areas, North America held a significant share of the market in the year 2023.

Some of the major players operating in the market include MediciNova, Inc.; Aphios Corporation; Braeburn Inc.; Alkermes; Indivior PLC; Zynerba Pharmaceuticals, Inc.; Mylan N.V.; Janssen Global Services, LLC; Sandoz AG; Cumberland Pharmaceuticals Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Opioid Use Disorder (OUD) Treatment Market
• 2.2. Research Methodology of the Opioid Use Disorder (OUD) Treatment Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL OPIOID USE DISORDER (OUD) TREATMENT MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DRUG CLASS

• 7.1. Buprenorphine
• 7.2. Methadone
• 7.3. Naltrexone

8.MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 8.1. Oral
• 8.2. Parenteral

9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies & Stores
• 9.3. Online Pharmacies

10.MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Spain
  • 10.2.5. Italy
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. India
  • 10.3.3. Japan
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of the World

11.TREATMENT LANDSCAPE OF OPIOID USE DISORDER

12.VALUE CHAIN ANALYSIS

• 12.1. Marginal Analysis
• 12.2. List of Market Participants

13.COMPETITIVE LANDSCAPE

• 13.1. Competition Dashboard
• 13.2. Competitor Market Positioning Analysis
• 13.3. Porter Five Forces Analysis

14.COMPANY PROFILES

• 14.1. MediciNova, Inc.
  • 14.1.1. Company Overview
  • 14.1.2. Key Financials
  • 14.1.3. SWOT Analysis
  • 14.1.4. Product Portfolio
  • 14.1.5. Recent Developments
• 14.2. Aphios Corporation
• 14.3. Braeburn Inc.
• 14.4. Alkermes
• 14.5. Indivior PLC
• 14.6. Zynerba Pharmaceuticals, Inc.
• 14.7. Mylan N.V.
• 14.8. Janssen Global Services, LLC
• 14.9. Sandoz AG
• 14.10. Cumberland Pharmaceuticals Inc.

15.ACRONYMS & ASSUMPTION

16.ANNEXURE